FDA approves new schizophrenia drug Cobenfy, first in 70 years

The U.S. Food and Drug Administration has approved Cobenfy, a new drug for schizophrenia, marking the first new class of treatment in over 70 years. Cobenfy combines two drugs, xanomeline and trospium, targeting different brain receptors than current medications. Current antipsychotics often cause significant side effects, including weight gain and sedation. Cobenfy aims to provide a more targeted treatment option, potentially improving the quality of life for patients. Its approval follows decades of research and development. Cobenfy's availability in Australia is uncertain, as the Therapeutic Goods Administration has not yet received an application for registration. Experts believe it could be a valuable addition to existing treatments, but its cost may be a concern without government subsidies.